PREVENTING PNEUMOcoccal disease through vaccination (study 2)
Research type
Research Study
Full title
A Phase IV Double Blind Randomised Controlled Trial (DBRCT) to Investigate the Effect of PCV-13 and PPV-23 on Pneumococcal Colonisation Using the Experimental Human Pneumococcal Challenge (EHPC) Model in Healthy Adults
IRAS ID
276247
Contact name
Andrea Collins
Contact email
Sponsor organisation
Liverpool School of Tropical Medicine
Eudract number
2019-004742-15
Duration of Study in the UK
1 years, 10 months, 28 days
Research summary
In the UK, there are 2 vaccines currently used to provide protection against pneumococcus. PCV-13 (Prevenar 13) protects against 13 (of >90) strains of pneumococcus and is routinely given to children ≤12 months of age. PPV-23 (Pneumovax 23) protects against 23 strains and is routinely given to adults >65 years. Both are also used in children and adults with medical conditions that put them at higher risk of pneumococcal disease. However, better pneumonia vaccines are needed.
Research studies have shown that there is an increase in carriage and disease by some strains that should be covered by these vaccines; this is called ‘vaccine escape’. We do not know why this is occurring and want to learn more about how these vaccines pneumococcal carriage.
In this study we are exploring how these 2 pneumonia vaccines, when compared to a placebo (saline), affect nasal carriage in older adults with 2 different strains of pneumococcus – strains 3 and 6B. In this study we are aiming to recruit a total of 293 healthy adults aged 60 to 69 years old.REC name
North West - Liverpool Central Research Ethics Committee
REC reference
20/NW/0097
Date of REC Opinion
18 Mar 2020
REC opinion
Favourable Opinion